The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1348
Low-Dose Doxepin (Silenor) for Insomnia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved a new low-dose formulation of the tricyclic antidepressant doxepin (Silenor – Somaxon) for treatment of insomnia associated with sleep maintenance. The manufacturer claims that this dose retains the hypnotic effect of doxepin, without typical tricyclic adverse effects. Doxepin is available generically in higher-strength capsules and in a liquid formulation.

MECHANISM OF ACTION — The usual dosage of doxepin for treatment of depression is 75-150 mg/day. At this dose, doxepin has antihistaminic and anticholinergic effects. Its affinity for H1-receptors, which is thought to be largely responsible for its sedating effect, is greater than its affinity for other receptors.1

CLINICAL STUDIES — In a double-blind trial, 565 healthy volunteers without insomnia were randomized to doxepin 6 mg or placebo. Efficacy was measured by ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Low-Dose Doxepin (Silenor) for Insomnia
Article code: 1348b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian